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Abstract
AIM
To study the published evidence on the impact of co-
lectomy in preventing recurrent primary sclerosing cho-
langitis (rPSC). 
METHODS
An unrestricted systematic literature search in PubMed, 
EMBASE, Medline OvidSP, ISI Web of Science, Lista 
(EBSCO) and the Cochrane library was performed on clini-
cal studies investigating colectomy in liver transplantation 
(LT) recipients with and without rPSC in the liver allograft. 
Study quality was evaluated according to a modification 
of the methodological index for non-randomized studies 
(MINORS) criteria. Primary endpoints were the impact of 
presence, timing and type of colectomy on rPSC. Overall 
presence of inflammatory bowel disease (IBD), time of 
IBD diagnosis, posttransplant IBD and immunosuppressive 
regimen were investigated as secondary outcome.
RESULTS
The literature search yielded a total of 180 publications. 
No randomized controlled trial was identified. Six retro-
spective studies met the inclusion criteria of which 5 
studies were graded as high quality articles. Reporting of 
IBD was heterogenous but in four publications, either in-
flammatory bowel disease, ulcerative colitis or in particular 
active colitis post-LT significantly increased the risk of 
rPSC. The presence of an intact (i.e.,  retained) colon at 
LT was identified as risk factor for rPSC in two of the high 
quality studies while four studies found no effect. Type of 
colectomy was not associated with rPSC but this endpoint 
was underreported (only in 33% of included studies). 
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Neither tacrolimus nor cyclosporine A yielded a significant 
benefit in disease recurrence of primary sclerosing 
cholangitis (PSC).
CONCLUSION
The data favours a protective role of pre-/peri-LT co-
lectomy in rPSC but the current evidence is not strong 
enough to recommend routine colectomy for rPSC pre-
vention. 
Key words: Recurrent primary sclerosing cholangitis; Risk 
factor; Ulcerative colitis; Colectomy; Liver transplantation
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: There are no known treatments that can alter 
the development and/or progression of recurrent primary 
sclerosing cholangitis (rPSC) after liver transplantation (LT). 
Shared leukocyte recruitment pathways of the gut-liver 
axis, bacterial translocation into the portal circulation from 
an inflamed gut and intestinal dysbiosis might contribute 
to the pathogenesis of rPSC. Indeed, inflammatory bowel 
disease, ulcerative colitis and in particular active colitis 
post-LT significantly increase the risk of rPSC and the 
available data favours a protective role of pre-/peri-LT co-
lectomy in rPSC. Prospective studies and randomized trials 
are needed to further elucidate a possible mechanistic link 
between retained colon and rPSC.
Buchholz BM, Lykoudis PM, Ravikumar R, Pollok JM, Fusai 
GK. Role of colectomy in preventing recurrent primary sclerosing 
cholangitis in liver transplant recipients. World J Gastroenterol 
2018; 24(28): 3171-3180  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v24/i28/3171.htm  DOI: http://dx.doi.
org/10.3748/wjg.v24.i28.3171
INTRODUCTION
Primary sclerosing cholangitis (PSC), a chronic inflam­
matory disease of the liver resulting in multi­focal 
strictures of the biliary tree[1], is estimated to recur in 
20%-25% of liver allograft recipients during the first de-
cade after liver transplantation (LT) with a mean interval 
to recurrent PSC (rPSC) of 6 mo to 5 years[2,3]. The 
diagnosis of rPSC is usually based on the Mayo criteria 
consisting of histological or cholangiographic features of 
PSC more than 90 d after LT in the absence of hepatic 
artery thrombosis/ stenosis, chronic ductopenic rejection, 
ABO incompatibility, anastomotic biliary strictures only, or 
non­anastomotic biliary strictures within 90 d after LT[4]. 
LT remains the only therapeutic option in patients 
with end stage liver disease from PSC and there are no 
known treatments that can alter the development and/or 
progression of rPSC after LT which oftentimes requires 
re­transplantation[1,5]. Different risk factors for rPSC 
have been identified by individual groups: Male recipient 
gender, cholangiocarcinoma identified on explant histo-
logy, extended criteria donor allograft, first-degree-
related donor and acute cellular rejection[6]. Although the 
association of ulcerative colitis (UC) and PSC is widely 
acknowledged[7], there is a lack of understanding with 
regards to the effect of UC on the risk of developing rPSC 
in LT recipients. 
Some authors have suggested that the presence of 
the colon at LT is associated with an increased risk of 
rPSC[8]. Three recent discoveries support a mechanistic 
link between the colon and PSC, and the same pathways 
that drive PSC in the non­transplant population might 
lead to the development of rPSC after LT. First, intestinal 
inflammation may fuel hepatic inflammation via shared 
leukocyte recruitment pathways of the gut-liver axis[9]. 
Homing molecules such as mucosal vascular addressin 
cell adhesion molecule 1 (MADCAM1) and the gut­as­
sociated chemokine (C­C motif) ligand 25, which are 
normally restricted to the gut, are abnormally upregu­
lated in the liver of PSC patients and facilitate the recruit­
ment of enteric­primed destructive α4β7­positive lympho­
cytes into the liver[10,11]. Additionally, as a consequence 
of intestinal inflammation, failure of the gut mucosal 
barrier with translocation of enteric pathogens to the 
portal circulation can drive hepatic inflammation via epi­
thelial pattern recognition receptor activation[9]. Third, 
independent from inflammatory bowel disease (IBD), 
intestinal dysbiosis was found to be associated with PSC, 
indicating that the intestinal microbiome might play a role 
in PSC pathogenesis[12]. This article reviews the published 
evidence on the role of colectomy in preventing rPSC in 
LT recipients.
MATERIALS AND METHODS
Literature search strategy
A comprehensive literature search was conducted using 
the databases of Pubmed, EMBASE, Medline OvidSP, 
ISI Web of Science, Lista (EBSCO) and the Cochrane 
library. Title, abstract, keywords and full-text of articles 
published in the time period from 1945 until 29th of April 
2018 were screened for the search terms which were 
stratified in blocks with rPSC (block 1), colectomy and 
ulcerative colitis (block 2), and liver transplant, immu­
nology and inflammatory bowel disease (block 3). All 
combinations were explored with one term each from 
block 1 and 2, subsequently combined with search terms 
from block 3 (Supplementary Figure 1). All languages 
and all publications on human subjects were considered. 
This unrestricted and unfiltered literature search was 
independently conducted by 2 authors (Buchholz BM 
and Lykoudis PM). Any disagreement was resolved by a 
third author (Fusai GK). The references of the identified 
publications were assessed for further reports pertinent 
to the topic.
Study selection
Articles were selected for final review if they compared 
LT recipients with and without rPSC, and reported at 
least one of the defined outcome endpoints. If the same 
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patient cohort was included in multiple publications, 
only the most recent update with the largest number of 
patients was retained. 
Quality assessment of studies
The quality of publications identified by the above li­
terature search was evaluated using a modification of 
the methodological index for non-randomized studies 
(MINORS) criteria, consisting of 9 items categorized into 
study design (clearly stated aim, inclusion of consecutive 
patients, prospective collection of data, endpoints ap­
propriate to the aim of the study), data recording and 
data quality (appropriate follow­up period, loss to follow­
up reporting, baseline equivalence of groups) and 
study assessment (outcome evaluation bias, adequate 
statistical analysis)[13]. The items were scored as 0 (not 
reported), 1 (reported but inadequate) or 2 (reported 
and adequate) with the ideal score being 18. The study 
evaluation for the MINORS criteria was independently 
performed by 2 authors (Buchholz BM and Lykoudis 
PM), and discrepancies were resolved by consensus with 
a neutral referee (Fusai GK). Given the above outlined 
natural history of rPSC, a follow­up time of 5 years after 
liver transplantation was set as appropriate. 
Primary and secondary endpoints
The primary outcome was the impact of presence (yes 
or no), timing (pre­/peri­LT or post­LT) and type of co­
lectomy (pan­proctocolectomy, segmental/subtotal or 
other) on rPSC in the liver allograft. The following end­
points were assessed as secondary outcomes: (1) Pre-
sence of IBD, time of IBD diagnosis (pre­LT, de novo), 
and post­transplant presence of IBD; and (2) primary 
and secondary immunosuppression. Further parameters 
were collected on recipient characteristics (recipient age 
at LT, recipient gender, MELD at LT, time to diagnosis of 
rPSC, and follow­up period) and donor demographics 
[donor age, donor gender and type of donation (DBD, 
DCD)]. The data of interest was extracted and tabulated 
from the relevant studies texts, tables and figures, by 2 
independent authors (Buchholz BM and Lykoudis PM). 
Data are reported as n (%) and median (interquartile 
range) unless otherwise indicated.
Biostatistics
The statistical methods of this study were reviewed by 
one of the authors (Lykoudis PM) Apart of the descriptive 
median MINORS score, no meaningful statistical ana­
lysis was feasible in this systematic review given the 
heterogeneity of the statistical methods applied for the 
described endpoints in the included original studies.  
RESULTS
The systematic literature search of the databases yielded 
a total of 180 publications (Figure 1). No article was iden­
tified in the Cochrane Library or Lista (EBSCO) and no 
additional records were retrieved from the manual search 
of the reference lists. Following removal of duplicates, 
56 studies were screened of which 43 were excluded on 
title screening (n = 7) and abstract screening (n = 36) as 
not pertinent to the topic. The full-text of the remaining 
14 publications was assessed for eligibility. Publications 
reporting on a smaller proportion of the same patient 
population as larger studies[8], conference abstracts[14,15] 
and cohort studies[16,17] were further excluded leaving a 
selection of 8 studies eligible for quality assessment.
Quality assessment of selected publications
All retrieved publications had an observational and retro­
spective design; no randomized controlled trial was iden­
tified. Two studies did not report any relevant endpoints 
and were therefore excluded in retrospect[18,19]. Hence, 
a total of 6 reports comparing LT recipients with and 
without rPSC in contemporary groups were assessed by 
MINORS criteria[20­25]. The median MINORS score was 11 
(IQR 8.75­12.25), with incomplete outcome reporting, 
lack of equivalent groups and failure to adequately state 
loss to follow up accounting primarily for lower scores 
(Table 1). There was evidence in outcome evaluation 
bias in all but two studies[20,25]. The study design was 
overall good with reporting of consecutive patients in all 
publications and a clearly formulated study aim in most 
reports, but only one study reported all endpoints[25]. 
Follow­up period and statistical methods were appro­
priate apart from one study published by Gelley et al[22]. 
The latter study therefore scored overall low quality (5 
points) while 5 publications were deemed of good quality 
with a MINORS score ranging from 10 to 13. These 
included single-centre experiences[20,21,24] as well as two 
large multi­centre cohorts[23,25]. The patient cohort of 
the multi­centre report by Ravikumar et al[25] overlaps 
in part with two single­centre studies[20,21] but does not 
completely capture the patient data; therefore, all three 
publications were retained.
Recipient and donor demographics
The retrieved studies on rPSC were published within 
the last decade and captured patient data from 1986 to 
2011. The indication for LT was PSC in all patients and LT 
recipients were followed up for a median time of 5.7 to 9.1 
years (Table 2). Follow­up was restricted by patient death 
but extended up to 8 to 22 years in the various studies. 
Diagnosis of rPSC was guided by Mayo criteria[4] in all 
studies and median time to diagnosis of rPSC ranged 
from 3.4 to 5 years as reported by 4 studies.    
Demographics were analyzed and described by dif­
ferent statistical methods in the various studies and can 
therefore only be compared in a descriptive manner. 
rPSC was more prevalent in patients undergoing a first 
liver transplant at a younger age. Similarly, there was a 
predominance of male gender in the rPSC group, with 
a higher MELD at LT. Liver grafts from younger donors 
were also associated with rPSC. Donor gender and donor 
type were rarely reported; however, the available data 
suggested no relevant differences between groups. It is 
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Inflammatory bowel disease
PSC develops in 2.4% to 7.5% of patients with inflam-
matory bowel disease (IBD) while 70% to 85% of pa­
tients with PSC will manifest symptoms of IBD during 
their lifetime[26]. Of the two distinct subtypes of IBD, 
ulcerative colitis has the strongest association with PSC 
accounting for 90% of the cases[7]. In line with this, data 
from Hildebrand et al[23] indicate that rates of IBD exceed 
the presence of UC in both rPSC and non­rPSC groups by 
approximately 10%. The majority of the studies (3 out of 
4) stated a higher rate of IBD in LT recipients with rPSC 
ranging between 86% to 100% compared to the non­
rPSC group (71%-79%) with the exception of Alabraba 
noticeable that almost exclusively livers from donors after 
brain death were utilized, a fact that is likely explained by 
era of transplantation prior to increased transplantation 
of organs from donors after circulatory death.    
Recipient factors such as younger age and advanced 
severity of liver disease were described as independent 
risk factors for rPSC (Table 3) but are given at the 
time of transplantation; it is logical that these cannot 
be addressed with the aim to improve outcome. The 
studies further suggest that a better graft selection 
with avoidance of donors with extended criteria, higher 
age and higher body mass index (BMI) could aid in pre-
venting rPSC. 
Studies excluded
(n  = 2)
 No endpoints reported (n  = 2)[18,19]
Records identified through
database searching
(n  = 180)
Additional records identified
through other sources
(n  = 0)
Records excluded
(n  = 43)
 Title screening (n  = 7)
 Abstract screening (n  = 36)
Full-text articles excluded
(n  = 5)
 Duplication of data (n  = 1)[8]
 Conference abstract (n  = 2)[14,15]
 Cohort studies (n  = 2)[16,17]
Records after duplicates removed
(n  = 56)
Records screened
(n  = 56)
Full-text articles assessed for
eligibility
(n  = 13)
Studies included in qualitative
assessment
(n  = 8)
Studies included in review
(n  = 6)
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Figure 1  PRISMA flowchart depicting literature search. References are indexed by superscript numericals.
Study design Data recording and data quality Study assessment MINORS 
score
Ref. Year Study 
aim
Consecutive 
patients
Data 
collection
Reported 
endpoints
Equivalent 
groups
Follow-up 
period
Loss to
 follow-up
Outcome 
evaluation 
bias
Statistical 
methods
Cholongitas et al[21] 2008 2 2 1 1 0 2 0 1 2 11
Alabraba et al[20] 2009 2 2 1 1 0 2 0 2 2 12
Moncrief et al[24] 2010 1 2 1 1 0 2 0 1 2 10
Gelley et al[22] 2014 1 2 1 1 0 0 0 0 0 5
Ravikumar et al[25] 2015 2 2 1 2 0 2 0 2 2 13
Hildebrand et al[23] 2016 2 2 1 1 0 2 0 1 2 11
Table 1  Methodological index for non-randomized studies criteria for selected studies on recurrent primary sclerosing cholangitis 
after liver transplantation
MINORS: Methodological index for non-randomized studies.
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et al[20] who observed an equivalent rate of IBD presence 
between groups reaching 72% and 70%, respectively 
(Table 4). Two studies exclusively reported on ulcerative 
colitis (UC) with a higher prevalence of UC in rPSC (78% 
­100%) vs non­rPSC (52%­56%)[21,25].
The available results of 4 studies on timing of IBD/
UC diagnosis demonstrates that IBD/UC occurs more 
frequently in LT recipients with rPSC both prior to trans­
plantation (65%­83% vs 46%­74%) and de novo after 
transplantation (13%­29% vs 2%­6%). There is also 
consensus amongst reports that the overall presence of 
IBD/UC after LT is considerably higher in cases of rPSC 
(65%­100% vs 42%­79%). IBD, either by presence of 
UC post­LT[21,23,25] or severe active IBD[22,23], was reported 
as an independent risk factor for disease recurrence of 
PSC in the liver allograft in four studies which included 
the two multi­centre studies (Table 3). 
Presence, timing and type of colectomy
None of the identified publications focused on the role 
of colectomy in prevention of rPSC, but some of them 
examined it within a broader assessment of risk factors 
for rPSC. Colectomy at any time was carried out at lower 
(7%­14% vs 20%­26%)[21,24] or equal rates (23%­34% 
vs 18%­32%)[20,22,25] in LT recipients with rPSC compared 
to the PSC cohort without recurrent disease in the liver 
allograft. The timing of colectomy, reported in 5 out of 6 
studies, differed consistently between the two groups: 
colectomy in patients with rPSC was performed mainly 
post­LT (14%­34% vs 10%­13%) and less often pre­ 
and peri­LT (0­7% vs 8%­21%) (Table 4). Two of the 
high quality studies conclude that (pre­/peri­LT) colectomy 
has a protective effect on rPSC in the liver allograft as the 
presence of a non­resected colon at transplantation was 
identified as a risk factor for rPSC on univariable analysis 
(Table 3)[20,25]. The remaining four publications reported 
no significant effect of colectomy on rPSC[21­24]. Still, as a 
trend towards a role of colectomy in preventing rPSC was 
found in some of the aforementioned studies, the lack of 
significance may be related to a type 2 statistical error as 
frequently seen in underpowered studies.
Data on the type of colectomy in the identified publi-
cations is scarce and contradictory. Segmental/subtotal 
colectomy was more often described in the multi­centre 
study by Ravikumar et al[25] while pan­proctocolectomy 
(specifically post­LT) was the preferred colorectal ap­
proach in LT recipients with rPSC in the work of Alabraba 
et al[20]. Pan­proctocolectomy was compared to other 
forms of colectomy in which remnant colorectal tissue 
remained in situ (segmental/subtotal colectomies and 
ileoanal pouch). Disregarding timing of colectomy, the 
overall assessment of type of colectomy revealed no 
significant difference in the risk for rPSC in LT recipients 
in both of the aforementioned studies. However, in the 
subgroup of post­LT colectomies, the risk of rPSC was 
significantly lower in patients who had undergone either 
pan­proctocolectomy or subtotal colectomy compared 
with LT recipients with ileoanal pouch[20]. 
Immunosuppression
Tacrolimus and cyclosporine A were used as mainstay 
immunosuppression in all identified studies. In the group 
with rPSC, the main choice of calcineurin inhibitor (CNI) 
was cyclosporine A (71%­72%) in two reports[20,21] and 
tacrolimus (44%­67%) in three publications[22,23,25], 
while the two drugs were utilized in a similar fashion in 
the study of Moncrief et al[24] (Table 4). Compared to 
LT recipients without rPSC, cyclosporine A was more 
Ref. Year Study 
period
Number n
(rPSC vs  
no rPSC)
Time to 
diagnosis of 
rPSC (yr)
Follow-up 
(yr)
Recipient 
age at LT 
(yr)
Recipient 
gender 
(male)
MELD at LT Donor age 
(yr)
Donor 
gender 
(male)
Donor type 
(DBD)
Cholongitas 
et al[21]
2008 1989-2004 7 (13) 
vs 
46 (87)
5 (0.3-10)1 9.1 (1-15.4)1 35 ± 15 
vs 
42 ± 132
5 (71) 
vs 
25 (54)
NR 33 ± 18 
vs 
44 ± 142
6 (86) 
vs 
27 (59)
NR
Alabraba 
et al[20]
2009 1986-2006 61 (23) 
vs 
202 (77)
4.6 (0.5-12.9)1 6.9 (0-19.9)1 48 (16-72)1 50 (82) 
vs 
149 (74)
NR NR NR 61 (100)
vs
202 (100)
Moncrief 
et al[24]
2010 1989-2006 15 (25) 
vs 
44 (75)
3.4 (1.5-5.5) 5.7 (2.8-8.8) 45 (36-53) 
vs 
47 (37-52)
13 (87) 
vs 
33 (75)
18 (13-21) 
vs 
14 (10-21)
NR NR NR
Gelley 
et al[22]
2014 1995-2011 6 (24) 
vs 
19 (76)
NR NR 27 ± 7 
vs 
37 ± 122
3 (50) 
vs 
13 (68)
16 ± 5 
vs 
11 ± 42
39 ± 14 
vs 
35 ± 112
NR NR
Ravikumar 
et al[25]
2015 1990-2010 81 (14) 
vs 
484 (86)
NR 9 (5-14) 43 (34-55) 
vs 
49 (41-57)
61 (75) 
vs 
344 (71)
NR 39 (28-53) 
vs 
43 (32-54)
46 (57) 
vs 
268 (55)
80 (99)
vs
467 (96)
Hildebrand 
et al[23]
2016 1990-2006 62 (20) 
vs 
243 (80)
4.6 (0.5-14.3)3 8.2 (0-22)3 39 ± 11.5 
vs 
39 ± 10.82
48 (77) 
vs 
160 (66)
16 ± 6 
vs 
14 ± 72
43.6 ± 16 
vs 
40.1 ± 16.92
NR NR
Table 2  Demographics of study cohorts comparing liver transplantation recipients with and without recurrent primary sclerosing 
cholangitis in the liver graft 
Data are reported as n (%) and median (interquartile range) unless indicated as 1median (range), 2mean ± SD and 3mean (range). DBD: Donation after brain 
death; LT: Liver transplantation; MELD: Model of end-stage liver disease; NR: Not reported; rPSC: Recurrent primary sclerosing cholangitis.
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often administered in the group with rPSC in 4 studies 
(25%­72% vs 11%­47%)[20,21,24,25] and to an equal 
extent in the two remaining publications (33%-53% 
vs 26%­55%)[22,23]. The choice of CNI had no effect on 
the risk of rPSC in 5 out of 6 studies while Ravikumar et 
al[25] found that maintenance immunosuppression with 
cyclosporine A carried a 2­fold increased risk for rPSC on 
univariate analysis; however, the association between 
cyclosporine A use and rPSC was lost when adjusted for 
transplantation era and in the multivariable model.
Azathioprine and steroids were less frequently used 
long­term in LT recipients with rPSC in the multi­centre 
Ref. Year Presence of 
IBD
(ever)
Time of IBD 
diagnosis (pre-
LT/de novo)
Presence of 
IBD (post-
LT)
Time of 
colectomy
pre- and peri-
LT/post-LT
Type of colectomy Primary 
immunosuppression
Secondary 
immunosuppression
1Cholongitas 
et al[21]
2008 7 (100) 
vs 
26 (56)
5 (71)/2 (29) 
vs 
25 (54)/1 (2)
7 (100) 
vs 
26 (56)
0 (0)/1 (14) 
vs 
6 (13)/6 (13)
NR TAC 
2 (29) vs 25 (54)
CyA 
5 (71) vs 21 (46)
AZA 
3 (43) vs 22 (48)
OKT3 or ATG
2 (29) vs 11 (24)
Alabraba 
et al[20]
2009 39 (72) 
vs 
123 (70)
NR NR 1 (2)/14 (23) 
vs 
28 (16)/18 (10)
Panproctocolectomy
7 (13) vs 15 (8)
Segmental + subtotal
5 (9) vs 21 (12)
Ileoanal pouch
3 (6) vs 10 (6)
TAC 
16 (26) vs 104 (51)
CyA 
44 (72) vs 95 (47)
None 
1 (2) vs 3 (2)
OKT3 
0 (0) vs 2 (2)
Moncrief 
et al[24]
2010 15 (100) 
vs 
33 (75)
11 (73)/4 (27) 
vs 
31 (70)/2 (5)
13 (87) 
vs 
24 (55)
1 (7)/NR 
vs 
9 (20)/NR
NR TAC 
7 (47) vs 28 (64)
CyA 
8 (53) vs 14 (32)
NR
Gelley 
et al[22]
2014 6 (100) 
vs 
15 (79)
5 (83)/1 (17) 
vs 
14 (74)/1 (5)
6 (100) 
vs 
15 (79)
0 (0)/2 (34) 
vs 
4 (21)/2 (11)
NR TAC 
4 (67) vs 14 (74)
CyA 
2 (33) vs 5 (26)
NR
1Ravikumar 
et al[25]
2015 51 (78) 
vs 
220 (52)
42 (65)/9 (13) 
vs 
193 (46)/27 (6)
43 (66) 
vs 
181 (42)
5 (6)/14 (17) 
vs 
40 (8)/46 (10)
Panproctocolectomy: 
2 (2) vs 22 (5)
Segmental + subtotal: 
16 (20) vs 41 (8)
Other: 1 (1) vs 17 (4)
TAC 
36 (44) vs 330 (68)
CyA 
20 (25) vs 55 (11)
AZA 
26 (32) vs 212 (44)
MMF 
10 (12) vs 67 (14)
Steroids 
38 (47) vs 285 (59)
Hildebrand 
et al[23]
2016 53 (86) 
vs 
167 (71)
NR 48 (77) 
vs 
138 (59)
NR NR TAC 
41 (67) vs 150 (66)
CyA 
32 (53) vs 124 (55)
Steroids 
41 (70) vs 133 (60)
Table 4  Primary outcomes of study cohorts comparing liver transplantation recipients with and without recurrent primary sclerosing 
cholangitis in the liver graft 
Data are expressed as n (%). 1Studies reporting exclusively on ulcerative colitis. ATG: Anti-thymocyte globulin; AZA: Azathioprine; CyA: Cyclosporine A; 
IBD: Inflammatory bowel disease; LT: Liver transplantation; MMF: Mycophenolate mofetil; NR: Not reported; OKT3: Muromonab-CD3; TAC: Tacrolimus.
Ref. Year Colectomy IBD-specific risk factor for rPSC non-IBD risk factor for rPSC
1Cholongitas et al[21] 2008 No effect Presence of UC post-LT Need for maintenance steroids post-LT
Alabraba et al[20] 2009 Protective
(pre- and peri-LT)
Presence of intact (i.e., retained) colon 
(independent of IBD or UC)
EDC grafts
Moncrief et al[24] 2010 No effect None At least one episode of ACR
CMV mismatch
Gelley et al[22] 2014 No effect Severe active IBD Higher donor BMI
Younger recipient age
1Ravikumar et al[25] 2015 Protective
(univariate analysis)
Presence of UC post-LT Younger recipient age
Hildebrand et al[23] 2016 No effect IBD, UC, and in particular active colitis 
post-LT
Higher donor age
Higher INR at LT
Table 3  Summary of study outcomes on impact of colectomy on recurrent primary sclerosing cholangitis, inflammatory bowel 
disease-specific risk factors and non-inflammatory bowel disease-specific risk factors for recurrent primary sclerosing cholangitis
1Studies reporting exclusively on ulcerative colitis. ACR: Acute cellular rejection; BMI: Body mass index; CMV: Cytomegalovirus; EDC: Extended donor 
criteria; IBD: Inflammatory bowel disease; INR: International normalized ratio; LT: Liver transplantation; rPSC: Recurrent primary sclerosing cholangitis; 
UC: Ulcerative colitis. 
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study by Ravikumar et al[25], yet none of secondary 
immunosuppressant agents used were significantly asso-
ciated with rPSC. Three further publications mention 
choice and frequency of secondary immunosuppression 
and describe no difference in the use of OKT3, anti­
thymocyte globulin and steroids between the two study 
groups[20,21,23].
DISCUSSION
PSC is a complex liver disease characterized by chronic 
inflammation of the biliary epithelium[1]. The patho­
genesis is not fully understood but immune dysregulation 
in genetically susceptible individuals is thought to play a 
major role[27]. Noticeably, PSC recurs in only one fifth of 
the transplant population[28] which implies that the natural 
course of PSC is altered after LT. As universally required 
in solid organ transplantation, management of the 
transplanted patient includes immunosuppression which 
might partially downregulate the immune pathways in­
volved in the development of PSC. The CNI tacrolimus 
and cyclosporine A remain the cornerstone of modern 
treatment regimens to reduce allograft rejection[29]. Both 
drugs inhibit different stages of the T­lymphocyte and 
B­lymphocyte activation cycles by interfering with the 
interleukin­2 pathway but bind to diverse intracellular 
target molecules[30] and differ in potency and spectrum of 
immune modulation[31]. 
However, none of the immunosuppressive regimen 
utilized in the selected studies conveyed a significant 
benefit in disease recurrence of PSC. Assuming that 
the analyzed studies reflect real world practise and that 
no true differences exist between the two CNI affecting 
the development of rPSC, this would imply that both 
drugs either do not target the hypothesized immune 
mechanisms of rPSC or do so in a similar fashion. The 
latter seems unlikely given the fact that the use of tacro­
limus is associated with increased IBD activity and the 
development of de novo IBD post­LT[32]. In line with 
this, a large Nordic cohort study identified tacrolimus 
as independent risk factor for rPSC[17]. On the other 
hand, bearing in mind that tacrolimus is more potent in 
preventing liver allograft rejection[31] and that acute cel­
lular rejection can drive rPSC (Table 3)[24,33], one would 
choose tacrolimus as the preferred immunosuppressive 
regimen with regard to prevention of rPSC. It remains 
possible that the significance of cylosporine A as a risk 
factor for rPSC was lost in the work of Ravikumar et 
al[25] due to high statistical dependence with another 
variable, something that could be further investigated by 
Spearman’s rank correlations in future studies[34].
Suggestions have been made that the selection of 
better quality grafts could aid in preventing PSC[22,23,25]; 
however, the translation of such an approach might prove 
difficult in the era of organ shortage as more marginal 
grafts are utilized to expand the donor pool[35]. It is 
especially recognized that the donor age has significantly 
increased over the past decades and continues to rise[36]. 
The impact of new technologies such as normothermic 
machine perfusion of marginal liver grafts on rPSC will 
have to be awaited[37]. Yet, it is encouraging that newer 
studies have reported that liver grafts from donors after 
circulatory death can be safely utilized in LT candidates 
with PSC and, although the incidence of ischemic­type 
biliary lesions was increased in the donor group after 
circulatory death compared to donors after brain death, 
the incidence of anastomotic strictures or rPSC was not 
different between donor groups[38].  
Considering the overall limitations in donor selection, 
the main targets in preventing rPSC appear to be factors 
in the management of the LT recipient such as frequently 
co-existing inflammatory bowel disease. Interestingly, 
it has been recently described that the coexistence of 
both ulcerative colitis and PSC in the same patient is 
associated with an increased risk of native liver disease 
progression and either need for liver transplantation or 
death[39]. Given the overall increased incidence of IBD in 
rPSC, it may therefore be hypothesized that the same 
pathways that drive PSC in the non­transplant popu­
lation are engaged in the development of rPSC after LT 
such as shared leukocyte recruitment pathways of the 
gut-liver axis[10,11] and bacterial translocation into the 
portal circulation from an inflamed gut[9]. While it was 
reported that active colitis and the need for maintenance 
steroids (> 3 mo), mainly reflecting UC activity and not 
graft dysfunction, significantly predispose to rPSC[21,23], 
the distinct impact of disease severity of IBD on rPSC 
has not been well assessed in the present studies. 
Cholongitas et al[21] are the only study that reported in 
more detail that UC disease extension (distal or total), 
UC activity per se, and the post­LT course of UC in terms 
of severity, number of admissions for UC and utilization 
of immunosuppression for UC exacerbation was not as-
sociated with rPSC. Controversy however exists about 
the clinical course of pre-existing IBD post-LT in general 
as conflicting data either point towards ameliorated 
bowel disease[40,41] or reports poorly­controlled IBD 
exacerbation[42,43]. De novo IBD after LT occurs at a var­
iable incidence of 1.3%­31.3%[42]. The 10­year risk to 
develop de novo IBD in the transplanted PSC population 
is estimated to be 14%­30% with a median time to 
onset of 4 years[44]. Even though de novo IBD usually 
presents later after transplantation and responds better 
to medical therapy compared to IBD recurrence[43], it 
has paradoxically been shown in the multi-centre study 
by Ravikumar et al[25] that the diagnosis of de novo UC 
was associated with a higher risk of rPSC compared to 
UC diagnosis prior LT. Liver cirrhosis attenuates T­cell 
function and the aforementioned finding raises the in­
teresting question whether rPSC is driven by restored 
T­cell function as it has been implemented for increased 
IBD disease activity of previously quiescent colitis[45].
The leading indications for colectomy in patients with 
concomitant UC and PSC are the presence of colorectal 
neoplasia and severe colonic inflammation in both the 
pre­ and post­transplant setting[32,46]. The overall neces­
sity for colectomy due to disease activity of UC was found 
to be reduced in patients with advanced PSC needing 
liver transplantation[47]. Yet, colectomy prior to but not 
after PSC diagnosis is beneficial leading to a decreased 
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risk of liver transplantation or death[48]. It was therefore 
especially relevant to analyze the identified studies 
regarding the impact of timing and type of colectomy 
on rPSC as it can be hypothesized that the prognosis of 
the liver allograft is altered depending on exposure to 
the UC environment or complete eradication of intestinal 
inflammatory factors and the intestinal microbiome 
prior to graft implantation. Within the limitations of retro­
spective publications, the data overall supported a protec­
tive role of colectomy in rPSC if carried out prior to or at 
the time of LT. The fact that intestinal dysbiosis has been 
implemented in the pathogenesis of PSC[12] and therefore 
possibly also rPSC, could explain why the presence of an 
intact (i.e., retained) colon post-LT significantly increased 
the risk of rPSC in the Birmingham series independently 
of colonic inflammation[20]. The included studies have 
not investigated whether the specific subpopulation of 
LT recipients with rPSC undergoing re­transplantation 
for graft failure represent a highly selected subgroup of 
patients that would in particular benefit from colectomy 
prior to or at the time of regrafting. This is something 
that could be investigated in future prospective studies or 
within the setting of a controlled study.
Peri­transplant morbidity and mortality associated 
to the previous colectomy procedure and complications 
arising from colectomy after LT were not investigated 
by any of the included studies. It is however known from 
the literature that the postoperative morbidity is high in 
colectomy in cirrhotic PSC patients. In particular, haemor­
rhagic complications and worsening liver function as well 
as sever liver failure requiring rescue LT are frequently 
encountered and are therefore of major concern[46,49,50]. 
Although historic reports on proctocolectomy in patients 
with PSC/UC have described no effect on patient survival 
in the pre­transplant setting[51], it is now recognized that 
mortality due to septic shock and hepatic failure occurs 
in pre­LT colectomy indicating that a simultaneous ap­
proach with colectomy at the time of transplantation 
might be better considered in patients with advanced 
PSC[46,49]. The type of colectomy appears without effect 
on the risk of rPSC, although one study found a higher 
risk of rPSC in LT recipients who underwent ileoanal 
pouch formation post­LT[20]. Although not reported in the 
selected studies and unrelated to rPSC, it should be taken 
into consideration that poor functional outcome as well 
as high rates of pouchitis (up to 90%) and pouch failure 
occur after ileoanal pouch formation in PSC patients[42,52].
It is a limitation of this review that only retrospective 
and observational reports were available to investigate 
the role of colectomy in rPSC. Furthermore, compared 
to other topics, a rather small number of studies were 
identified and included in our analysis. However, the 
selected studies were mainly of high quality and therefore 
reliably present the best evidence available.
In conclusion, this systematic review revealed no 
prospective or matched studies with comparative data 
on rPSC and non­rPSC. The identified retrospective, 
observational reports were mainly of high quality and 
examined the impact of colectomy on liver disease re-
currence within a broader assessment of risk factors 
for rPSC. Within the limitations of scarce retrospective 
publications, the available data supports a protective 
role of colectomy in rPSC if carried out prior to or at the 
time of LT. This was indirectly underpinned by the strong 
association of rPSC with IBD, UC and in particular active 
colitis post­LT. The heterogeneity in the presentation of 
UC and its progression as well as the general difficulty in 
grading severity of IBD explain the lack of publications 
correlating bowel disease severity and colectomy in the 
development of rPSC. Choice of immunosuppression 
did not affect rPSC and pan­proctocolectomy was not 
superior compared to other forms of colectomy (ileoanal 
pouch and segmental­/­subtotal colectomies) in which 
residual colorectal tissue or intestinal microbiota could 
fuel immunopathogenic pathways. Taken together, the 
overall evidence is not strong enough to advocate routine 
colectomy. Prospective, matched studies and randomized 
trials on timing and type of colectomy in LT candidates 
with PSC, which should include analysis of peri­colectomy 
morbidity, are warranted for an adequate risk­benefit 
decision. However, as graft selection is limited in the 
era of marginal organ utilization, pre­ or peri­LT timing 
of colectomy in LT candidates that are likely to require 
colectomy in due time based on IBD activity is a route 
that could be further explored with a view to improve 
outcomes after LT for PSC.
ARTICLE HIGHLIGHTS
Research background
Recurrence of PSC (rPSC) following liver transplantation occurs in up to a 
quarter of transplant recipients. Prophylactic colectomy has been proposed as 
a strategy to reduce the incidence of rPSC.
Research motivation
Current literature on the benefit of prophylactic colectomy for prevention of rPSC 
post liver transplantation does not include any randomized controlled trials. 
Findings of reported studies need thus to be examined in a critical way, to assess 
strength of current evidence and to highlight areas for future improvement.
Research objectives
This study aims to critically review the existing evidence regarding prophylactic 
colectomy for prevention of post liver transplant rPSC, to evaluate reported 
studies and to identify shortcomings that should be addressed in future studies.
Research methods
A systematic review was carried out, using structured search terms and a 
reproducible study selection procedure. Data were extracted and tabulated. 
The quality of the included studies was evaluated according to modified 
methodological index for non-randomized studies criteria. 
Research results
From a total of 180 publications, 6 were included in the final analysis and all of 
them were retrospective cohort studies. There was significant heterogeneity in 
the studied samples, regarding other prognostic factors as well as timing and 
type of colectomy, but the overall evidence favoured a protective role of pre-/
peri- liver transplantation (LT) colectomy in rPSC. 
Research conclusions
This study reviews and reports the results of the existing literature in a systematic 
and objective way. In the absence of randomized prospective studies, such an 
approach is indicated for drawing conclusions based on findings of retrospective 
cohort studies. It confirms the overall impression that colectomy might convey 
protection against rPSC after LT, but the current literature cannot provide definite 
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answers. Finally, our work identifies a lack of comparable groups and failure to 
report loss to follow-up as the main limitations of reported studies. 
Research perspectives
According to the findings of the present study, prophylactic colectomy seems to 
play a protective role in rPSC post LT, but the existing evidence is not strong. 
The question would be better answered through prospective randomized 
trials. It is understood though that such attempt might face several difficulties, 
particularly in terms of sample size. Alternatively, if retrospective studies 
were to be carried out, they should include comparison between two groups, 
those who undergo prophylactic colectomy and those who don’t, and patients’ 
characteristics, follow-up and outcomes should be reported in a more detailed 
way. 
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